Moderna Inc's MRNA CEO, Stephane Bancel, told Reuters that an omicron-specific booster could be ready by August.
- The CEO said that the firm is still gathering clinical data to determine whether that vaccine would offer better protection than a new dose of the existing jab.
- Last month Moderna began clinical trials for a booster dose specifically designed to target omicron. Initial results from studies in monkeys show that the omicron-specific shot may not offer stronger protection than a new dose of the existing vaccine.
- Related: Moderna-Rovi Seal 10-Year Deal Extension To Make mRNA Drugs.
- "We believe a booster will be needed. I don't know yet if it is going to be the existing vaccine, omicron-only, or bivalent: omicron and existing vaccine, two mRNA in one dose."
- He said a decision would be made when clinical data become available in the coming months.
- Bancel also confirmed that under the best-case scenario, Moderna would have pan-vaccine by August 2023, which would protect simultaneously against COVID-19, flu, and other respiratory diseases.
- Price Action: MRNA shares are down 1.35% at $149.76 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in